-
公开(公告)号：US20190233439A1
公开(公告)日：2019-08-01
申请号：US16299423
申请日：2019-03-12
发明人： Vincent Jacques , James R. Rusche , Norton P. Peet , Jasbir Singh
IPC分类号： C07D513/04 , C07D277/30 , C07D401/06 , C07D211/34 , C07D403/06 , C07D277/593 , C07D261/08 , C07D263/32 , C07D231/12 , C07D471/04
CPC分类号： C07D513/04 , C07D211/34 , C07D231/12 , C07D261/08 , C07D263/32 , C07D277/30 , C07D277/593 , C07D401/06 , C07D403/06 , C07D471/04
摘要： This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
-
公开(公告)号：US09981046B2
公开(公告)日：2018-05-29
申请号：US14401115
申请日：2013-05-14
发明人： Zhenwei Miao , Yufeng Hong , Tong Zhu
IPC分类号： C07D241/04 , A61K47/48 , C07D207/08 , C07D207/09 , C07D277/593 , C07D401/12 , C07D403/12 , C07F5/02 , C07K5/06 , A61K38/07 , A61K47/68
CPC分类号： A61K47/6855 , A61K38/07 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6889 , C07D207/08 , C07D207/09 , C07D277/593 , C07D401/12 , C07D403/12 , C07F5/025 , C07K5/06008
摘要： In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
-
公开(公告)号：US20170253554A1
公开(公告)日：2017-09-07
申请号：US15509214
申请日：2015-09-08
发明人： Yan Shi , Peter T.W. Cheng , Ying Wang , Sutjano Jusuf , Shiwei Tao , Hao Zhang , Shung C. Wu , Jeffrey A. Robl
IPC分类号： C07C62/34 , A61K31/192 , C07D307/79 , A61K31/343 , C07D277/30 , A61K31/44 , C07D213/55 , A61K31/4418 , C07D231/12 , A61K31/415 , C07D213/65 , A61K45/06 , A61K31/426
CPC分类号： C07C62/34 , A61K31/192 , A61K31/343 , A61K31/415 , A61K31/426 , A61K31/44 , A61K31/4418 , C07C59/64 , C07C2601/02 , C07D207/323 , C07D213/55 , C07D213/65 , C07D231/12 , C07D277/30 , C07D277/593 , C07D307/79 , C07D307/82
摘要： The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein coupled receptor modulators which may be used as medicaments
-
4.发明申请HETEROCYCLIC GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF 有权杂环化合物F1F0-ATP酶抑制剂及其治疗用途公开(公告)号：US20150148373A1
公开(公告)日：2015-05-28
申请号：US14403787
申请日：2013-06-07
申请人： Lycera Corporation
IPC分类号： C07D471/04 , C07D413/12 , C07D405/12 , C07D417/12 , C07D401/12 , C07D231/38 , C07D277/593
CPC分类号： C07D471/04 , A61K31/415 , A61K31/42 , A61K31/443 , A61K31/4439 , A61K31/4525 , A61K31/454 , C07D231/14 , C07D231/38 , C07D231/40 , C07D277/56 , C07D277/593 , C07D307/68 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
摘要翻译： 本发明提供了抑制F1F0-ATP酶的杂环胍化合物，以及使用杂环胍化合物作为治疗药物治疗诸如免疫病症，炎性病症或癌症的医学病症的方法。
-
公开(公告)号：US20130190368A1
公开(公告)日：2013-07-25
申请号：US13825689
申请日：2011-08-23
申请人： Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Matta Ramakrishna Reddy , Bandi Vamsi Krishna
发明人： Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Matta Ramakrishna Reddy , Bandi Vamsi Krishna
IPC分类号： C07D277/593
CPC分类号： C07D277/593 , A61K31/426 , C07D277/56
摘要： The present invention provides a novel 1,4-dioxane solvate form of febuxostat and process for its preparation. The present invention also provides novel crystalline forms of febuxostat, processes for their preparation and pharmaceutical compositions comprising them.
摘要翻译： 本发明提供了一种新型的1,4-二恶烷溶剂合物形式的氟康酸钠及其制备方法。 本发明还提供了昂布斯他汀的新结晶形式，其制备方法和包含它们的药物组合物。
-
公开(公告)号：US09884127B2
公开(公告)日：2018-02-06
申请号：US14401114
申请日：2013-05-14
IPC分类号： A61K39/00 , A61K47/48 , C07D207/02 , C07D241/12 , C07D241/14 , C07D249/04 , C07D251/12 , C07D261/08 , C07D261/10 , C07D207/08 , C07D207/09 , C07D277/593 , C07D401/12 , C07D403/12 , C07F5/02 , C07K5/06 , A61K38/07 , A61K47/68
CPC分类号： A61K47/6855 , A61K38/07 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6889 , C07D207/08 , C07D207/09 , C07D277/593 , C07D401/12 , C07D403/12 , C07F5/025 , C07K5/06008
摘要： In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
-
7.发明授权Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 有权用于靶向递送至表达α-V-β-3的细胞的整联蛋白拮抗物缀合物公开(公告)号：US09586916B2
公开(公告)日：2017-03-07
申请号：US14374680
申请日：2013-01-22
发明人： Robert Alan Goodnow, Jr. , Matthew Michael Hamilton , Agnieszka Kowalczyk , Achyutharao Sidduri
IPC分类号： C07D207/452 , C07D239/14 , C07D417/12 , C07D277/593 , C07C327/32 , A61K47/48 , C07C237/52
CPC分类号： C07D277/593 , A61K47/545 , A61K47/549 , A61K47/60 , C07C237/52 , C07C327/32 , C07D207/452 , C07D239/14 , C07D417/12
摘要： The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.
摘要翻译： 本发明涉及式（I）的化合物：其中R 1，R 2和n在详细描述和权利要求书中定义。 特别地，本发明涉及用于制备和递送缀合部分的式（I）化合物，所述共轭部分例如小分子，肽，核酸，荧光部分和与α-V-β- 整合素拮抗剂靶向表达α-V-β-3的细胞。
-
公开(公告)号：US20170050984A1
公开(公告)日：2017-02-23
申请号：US15346877
申请日：2016-11-09
发明人： Vincent Jacques , James R. Rusche , Norton P. Peet , Jasbir Singh
IPC分类号： C07D513/04 , C07D231/12 , C07D263/32 , C07D401/06 , C07D471/04 , C07D403/06 , C07D211/34 , C07D277/593 , C07D261/08
CPC分类号： C07D513/04 , C07D211/34 , C07D231/12 , C07D261/08 , C07D263/32 , C07D277/593 , C07D401/06 , C07D403/06 , C07D471/04
摘要： This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
摘要翻译： 本发明涉及通常抑制组蛋白脱乙酰酶（“HDAC”）酶（例如HDAC1，HDAC2和HDAC3）。
-
公开(公告)号：US20120309762A1
公开(公告)日：2012-12-06
申请号：US13587516
申请日：2012-08-16
申请人： Larry L. Klein , Hui-Ju Chen , Ming C. Yeung , Charles A. Flentge , John T. Randolph , Peggy P. Huang , Douglas K. Hutchinson , Dale J. Kempf
发明人： Larry L. Klein , Hui-Ju Chen , Ming C. Yeung , Charles A. Flentge , John T. Randolph , Peggy P. Huang , Douglas K. Hutchinson , Dale J. Kempf
IPC分类号： C07D277/24 , C07D417/12 , A61K31/4439 , A61K31/426 , A61K31/427 , A61P31/12 , C07D417/14 , A61K31/5355 , A61K31/496 , A61K31/5377 , A61K31/454 , C12N9/99 , A61K31/513
CPC分类号： A61K31/5377 , A61K31/4164 , A61K31/4178 , A61K31/4439 , A61K31/4525 , A61K31/496 , A61K31/506 , A61K45/06 , C07D213/79 , C07D277/24 , C07D277/30 , C07D277/593 , C07D417/12
摘要： The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
-
公开(公告)号：US20110021771A1
公开(公告)日：2011-01-27
申请号：US12740616
申请日：2008-11-03
申请人： Tammy Mallais , Oscar Moradei , Alain Ajamian , Pierre Tessier , David Smil , Sylvie Frechette , Roger Machaalani , Silvana Leit , Patrick Beaulieu , Robert Déziel , John Mancuso
发明人： Tammy Mallais , Oscar Moradei , Alain Ajamian , Pierre Tessier , David Smil , Sylvie Frechette , Roger Machaalani , Silvana Leit , Patrick Beaulieu , Robert Déziel , John Mancuso
IPC分类号： C07D413/04 , C07D413/10 , C07D401/04 , C07D417/14 , C07D277/30 , C07D231/12 , C07D333/70 , C07D333/38
CPC分类号： C07D277/593 , C07C259/10 , C07C311/29 , C07D207/327 , C07D207/34 , C07D213/61 , C07D213/64 , C07D231/12 , C07D231/14 , C07D235/18 , C07D239/28 , C07D239/38 , C07D261/18 , C07D263/34 , C07D267/20 , C07D277/30 , C07D277/64 , C07D307/85 , C07D307/91 , C07D317/60 , C07D333/24 , C07D333/38 , C07D401/04 , C07D403/10 , C07D413/04 , C07D417/04 , C07D417/12 , C07D417/14
摘要： This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
摘要翻译： 本发明涉及抑制HDAC酶活性的化合物和方法。 更具体地，本发明提供式（I），（I）和N-氧化物，水合物，溶剂合物，药学上可接受的盐，前药和络合物的化合物，以及外消旋和可比混合物，非对映异构体和对映异构体，其中L，M ，n，R，W，X和Y如说明书中所定义。
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.024 秒)
